Reading DYN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DYN free→Reading DYN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DYN free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which could impact future performance. If DYN cuts guidance on the next call, that would be a meaningful negative, as the Street tends to walk down estimates and the stock usually takes a leg lower. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $18.07. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 80.55x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.80 → $-0.75 (+6.0% / 30d). 5 raised, 5 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d. 88% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$237.
How much price usually moves either way.
On a bad day, this stock has moved -$700.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,081.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Topline data will help decide if z-basivarsen can get a Biologics License.
Confirms:Topline data from the ACHIEVE trial shows good results for z-basivarsen.
Disproves:Topline data from the ACHIEVE trial shows negative results or delays.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for DYN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 3, 2026, the Company issued a press release announcing full enrollment of the REC of its Phase 1/2 ACHIEVE trial of z-basivarsen in individuals with DM1 with 71 participants. Additionally, the Company announced the following key milestones for z-basivarsen: • Topline data from the ACHIEVE REC are planned for the first quarter of 2027 to support a potential Biologics License Application (“BLA”) for U.S. Accelerated Approval in the third quarter of 2027. • The Company inte…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
DYN Dyne Therapeutics, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Ramp up activities to support the potential launch of z-rostudirsen in DMD by the first quarter of 2027.
Expect a potential U.S. launch of z-basivarsen in the first quarter of 2028.
Ensure cash, cash equivalents, and marketable securities are sufficient to fund operations into the first quarter of 2028.
Why it matters: A successful launch of z-rostudirsen is key for Dyne's growth and market strength.
Confirms:Management says the launch of z-rostudirsen is on track for Q1 2027.
Disproves:Management delays the launch of z-rostudirsen beyond Q1 2027.
Why it matters: Funding will affect Dyne's ability to keep running and launch new products.
Confirms one read:Management shares news about new funding or partnerships. This will help operations until Q1 2028.
Confirms the other:Management reports problems with funding. There are delays in getting needed capital.
Results of Operations and Financial Condition. On May 11, 2026, Dyne Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of t…
Results of Operations and Financial Condition. On March 2, 2026, Dyne Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of…
Results of Operations and Financial Condition. Dyne Therapeutics, Inc. (the “Company”) disclosed on January 12, 2026, that although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, it expects to report cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025. The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this Current Report o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 22, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders and until his successor has been d…